{"product_id":"tevapharm-swot-analysis","title":"Teva Pharmaceutical Industries SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eTeva faces a complex crossroads: deep generics expertise and a strong global footprint contrast with heavy debt, litigation exposure, and competitive pricing pressure, while biosimilars and specialty pipeline progress represent key growth levers—discover the full SWOT analysis to unlock actionable strategy and investment insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Global Leadership in Generic Pharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva remains one of the world’s largest generic drug makers, with ~3,000 marketed molecules and presence in 60+ countries, enabling broad therapeutic coverage and scale.\u003c\/p\u003e\n\u003cp\u003eScale drives manufacturing and procurement cost efficiencies; Teva’s 2024 gross margin for generics near 45%, boosting competitiveness in large public tenders.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 this leadership underpins stable revenue—generics comprise ~60% of Teva’s $10.5B FY2024 revenue—supporting market penetration and long-term contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Portfolio of Innovative Specialty Medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva has diversified revenue with specialty medicines like Austedo (Huntington's) and Ajovy (migraine); Austedo net sales were about $580m and Ajovy $670m in 2024, giving higher gross margins than generics. Strong patent protection—Austedo patents to 2032 and Ajovy to 2035—supports pricing power and recurring revenue. Growth in these brands helped Teva shift toward a more balanced, profitable mix, reducing reliance on low-margin generics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Global Manufacturing and Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeva runs 40+ manufacturing sites across North America, Europe, Asia and Israel, supporting sales to more than 60 countries and generating $14.3 billion revenue in 2024; this integrated network lets Teva shift production fast to meet demand and keep core generics stocked. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuccessful Execution of the Pivot to Growth Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUnder current leadership, Teva implemented a pivot-to-growth strategy that optimized the portfolio and refocused R\u0026amp;D, boosting adjusted EBITDA margin to about 18% in FY 2024 from 12% in 2021 and reducing net debt by roughly $6.5 billion through 2022–2024 deleveraging programs.\u003c\/p\u003e\n\u003cp\u003eThose moves improved cash flow, disciplined capex and M\u0026amp;A, and by late 2025 restored investor confidence—Teva’s share price rose ~40% from early 2023 lows and credit spreads tightened as rating agencies noted a stabilized long-term outlook.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdjusted EBITDA margin ~18% (FY 2024)\u003c\/li\u003e\n\u003cli\u003eNet debt cut ≈ $6.5bn (2022–2024)\u003c\/li\u003e\n\u003cli\u003eShare price +~40% since early 2023\u003c\/li\u003e\n\u003cli\u003eStronger cash flow, disciplined capex\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Research and Development Capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTeva runs advanced R\u0026amp;D centers targeting complex generics and novel therapies, delivering regular launches — 2024 saw ~20 complex-generic approvals and R\u0026amp;D spend of $1.1bn (FY2024).\u003c\/p\u003e\n\u003cp\u003eFocusing on high-barrier products like long-acting injectables and biosimilars cuts direct competition and lifts margins; biosimilars pilot programs aim for \u0026gt;$500m peak annual sales per successful molecule.\u003c\/p\u003e\n\u003cp\u003eTechnical strength in long-acting injectables and biosimilars supports sustainable market positions and lifecycle extensions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D spend $1.1bn (FY2024)\u003c\/li\u003e\n\u003cli\u003e~20 complex-generic approvals in 2024\u003c\/li\u003e\n\u003cli\u003eBiosimilar peak sales target \u0026gt;$500m each\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeva scales generics and specialty growth: $14.3B revenue, margins improving\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeva’s scale (≈3,000 molecules, 60+ countries) and integrated manufacturing (40+ sites) drove FY2024 revenue $14.3B and generics gross margin ~45%; generics ≈60% of $10.5B generics sales. Specialty brands Austedo $580M, Ajovy $670M (2024) plus R\u0026amp;D $1.1B and ~20 complex approvals in 2024 lift margins; adjusted EBITDA ~18% (FY2024) and net debt down ≈$6.5B (2022–2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ 2022–24\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$14.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics share\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics margin\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAustedo sales\u003c\/td\u003e\n\u003ctd\u003e$580M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAjovy sales\u003c\/td\u003e\n\u003ctd\u003e$670M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComplex approvals\u003c\/td\u003e\n\u003ctd\u003e~20\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. EBITDA margin\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt reduction\u003c\/td\u003e\n\u003ctd\u003e≈$6.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Teva Pharmaceutical Industries’s internal strengths and weaknesses and external opportunities and threats, highlighting its generic market leadership, R\u0026amp;D and debt challenges, growth avenues in specialty medicines and biosimilars, and regulatory, patent, and competitive risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a compact Teva SWOT snapshot for rapid strategic alignment, highlighting generics strength, debt risks, pipeline gaps, and M\u0026amp;A opportunities for clear executive decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Long-term Debt Obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite multi-year deleveraging, Teva still held about $18.5 billion of net debt by Q3 2025, forcing roughly $800–900 million in annual interest expense and constraining free cash flow for strategic moves.\u003c\/p\u003e\n\u003cp\u003eThis heavy servicing cost limits Teva’s ability to pursue large M\u0026amp;A or quickly reallocate capital to fast-growing specialty segments, slowing strategic agility.\u003c\/p\u003e\n\u003cp\u003eAlthough leverage ratios improved by late 2025 (net debt\/EBITDA near 3.0x), analysts still flag credit-rating and liquidity risk as primary concerns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Generic Price Erosion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe core generic business faces intense pricing pressure, especially in the US where the top 3 pharmacy benefit managers cover about 80% of lives, pushing down prices and gross margins — Teva’s US generics gross margin fell toward mid-teens in recent quarters (2024), down from ~20% in 2020. This deflationary trend can shrink profits even if unit volumes rise. Teva must continually launch new generics to replace older SKUs losing price, creating a costly, high-pressure development cycle. In 2024 Teva reported generic price erosion as a key headwind reducing adjusted EBITDA by hundreds of millions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Sensitivity to Legal Settlement Cash Outflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHistorical legal issues, notably opioid litigation and price‑fixing allegations, forced Teva Pharmaceutical Industries to agree to multi‑year settlements—including a 2020 U.S. opioid framework where Teva committed up to $4.25 billion over time and additional antitrust settlements totaling hundreds of millions—creating sustained cash outflows. These payments have cut free cash flow sharply; in 2024 Teva reported negative free cash flow of $0.6 billion, in part due to settlement funding. Ongoing scheduled payouts through 2025 limit capital for R\u0026amp;D, generics scale or buybacks. That fiscal drag reduces financial flexibility and raises refinancing risk for new investments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration Risk in Key Specialty Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTeva’s reliance on specialty drugs like Austedo (estimated 2024 net sales ~USD 900m) creates concentration risk: a regulatory setback or generic\/biologic competition could cut revenues sharply and hurt margins.\u003c\/p\u003e\n\u003cp\u003eIf growth in these core brands slows—Austedo growth slowed to low single digits in 2024—the firm may lack near-term replacements of similar scale, pressuring free cash flow and R\u0026amp;D allocation.\u003c\/p\u003e\n\u003cp\u003eBalancing the portfolio away from a few blockbusters remains a persistent strategic challenge for Teva.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 Austedo sales ~USD 900m — single-product exposure\u003c\/li\u003e\n\u003cli\u003eLow-single-digit growth in 2024 signals vulnerability\u003c\/li\u003e\n\u003cli\u003eRegulatory or competitive shock could drop revenues \u0026gt;10–20%\u003c\/li\u003e\n\u003cli\u003eNeed diversified pipeline; current replacements not immediate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity of Managing a Global Organizational Structure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpoperating across regulatory jurisdictions raises compliance and admin costs for teva in g expenses were reflecting this burden slowing unified strategy rollout.\u003e\n\u003cpmaintaining consistent quality across manufacturing sites requires continuous oversight recall-related costs hit peers up to so similar risks could materially affect margins.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003e60+ jurisdictions → higher G\u0026amp;A: $1.9B (2024)\u003c\/li\u003e\n\u003cli\u003e~50 plants → costly quality oversight\u003c\/li\u003e\n\u003cli\u003eStrategy delays across subsidiaries → execution risk\u003c\/li\u003e\n\n\u003c\/pmaintaining\u003e\u003c\/poperating\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy $18.5B debt, $800–900M interest, opioid settlements and product concentration risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy net debt (~$18.5B Q3 2025) drives $800–900M interest\/year, squeezing FCF and M\u0026amp;A capacity; US generics price erosion cut gross margins to mid-teens by 2024; ongoing opioid\/antitrust settlements (incl. up to $4.25B opioid framework) drain cash; product concentration (Austedo ~USD900M 2024) raises revenue risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e$18.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest expense\/year\u003c\/td\u003e\n\u003ctd\u003e$800–900M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAustedo sales (2024)\u003c\/td\u003e\n\u003ctd\u003e$900M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A (2024)\u003c\/td\u003e\n\u003ctd\u003e$1.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics gross margin (US, 2024)\u003c\/td\u003e\n\u003ctd\u003eMid-teens%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpioid settlement commitment\u003c\/td\u003e\n\u003ctd\u003eUp to $4.25B (2020)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eTeva Pharmaceutical Industries SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content is pulled from the final editable file.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752528032121,"sku":"tevapharm-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/tevapharm-swot-analysis.png?v=1772242018","url":"https:\/\/growthsharematrix.com\/products\/tevapharm-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}